Using a monoctonal antibody (LK2H10) directed against human chromogranin, we have been able to localize this soluble glycoprotein to the matrix of secretory granules from a wide varieW of endocrine cells. In the gut, en~erochromaffin, enteroglucagon, glucose-dependent insulinotropic peptide, gastrin, and neuroi:ensin-containing cells exhibit chromogranin immunoreactivity. In our system, chromograninimmunoreactive material was restricted to the halo of human pancreatic glucagon-containing secretory granules within A-ceils. Chromogranin immunoreactivity was also localized to secretory granules in phaeochromocytomas, gastrinomas, medullary carcinomas of the thyroid and a carotid body turnout (chemodectoma). Chromogranin is proposed as a potential marker for the ultrastructural recognition of endocrine cell secretory granules.
Introduction
The molecular composition of catecholamine-containing secretory (chromaffin) granules of the adrenal medulla has been analysed in considerable detail ( together with a group of highly acidic glycoproteins collectively referred to as chromogranins. Quantitatively, the major form of the secretory granule matrix soluble glycoproteins is chromogranin A which is chemically similar, if not identical, to secretory protein I of the parathyroid gland granules (Cohn et al., 1982 (Cohn et al., , 1984 .
Chromogranin A, which comprises about 40% of the soluble proteins in chromaffin granules (Winkler, 1976) , contains approximately 5.4% carbohydrate, predominantly 0-glycosidically linked trisaccharides (Kiang eta]., 1982) . The precise amino acid sequence of chromogranin A remains enigmatic (Winkler & Carmichael, 1982) , presumably because the purified molecule seems to be unstable (Kirshner, 1974) . Consequently, the published molecular weight for chromogranin A varies between 68 000 (human; O'Connor et al., 1984) and 74 000 to 81 200 (bovine; Smith & Winkler, 1967; Kirshner & Kirshner, I969; Helle, 1971) . Recently, the chromogranins have been characterized immunologically (Falkensammer et al., 1985) .
Using a monoclonal antibody (LK2H10) which recognizes one epitope of chromogranin, Lloyd & Wilson (1983) were able to demonstrate the efficacy of this system for the immunocytochemical recognition of endocrine tissue. In a subsequent publication and using the same LK2H10 antibody, Wilson & Lloyd (1984) detected chromogranin immunoreactivity in 126 normal and neoplastic endocrine tissues (with demonstrable secretory granules) but not in 113 cases of nonendocrine normal and neoplastic tissue or in 40 endocrine tissues or tumours without demonstrable secretory granules. Recently, our group conducted a systematic immunohistochemical investigation of the distribution of chromogranin in the human gastrointestinal tract (Facer et al., 1985) . We were able to demonstrate that chromogranin immunoreactivity, identified using antibody LK2H10, was a reliable marker for gut endocrine cells at the light microscope level, although some inconsistency in the degree of immunostaining was noted over the range of processing regimes adopted.
In the present study, we have attempted to demonstrate the ultrastructural localization of a human chromogranin epitope in a wide range of normal and neoplastic endocrine cells using a monoclonal antibody.
Materials and methods
Human tissue samples were obtained from surgery within 30 min of resection (see Table 1 ). The tissue was chilled on wet ice before fixation in cold 2.5% glutaraldehyde (25% ultrapure; EMScope Laboratories, Ashford, Kent, UK) in 0.1 M sodium phosphate buffer, pH 7.2, for 2 h. Following fixation and rinsing in phosphate buffer containing 0.I M sucrose, half of each sample was osmicated (1% osmium tetroxide in phosphate buffer for I h). All blocks were then rinsed and processed through ethanols into Araldite epoxy resin.
Ultrathin sections (silver to silver-grey) were cut and mounted onto cleaned, uncoated 300-mesh nickel grids.
Antibody LK2HIO
Antibody LK2HI0 was raised as described in detail by Wilson & Lloyd (1984) . Briefly, a BALB/c mouse was immunized with a minced human phaeochromocytoma-Freund's adjuvant emulsion (five bi-weekly intraperitoneal injections). Spleen cells were separated and fused with NS-1 mouse myeloma cells (Galfre et al., 1977) . Culture supernatant fluid from growing clones was then screened for antibody activity against cryostat sections of the original tumour. Hybridoma LK2H10 was selected and sub-cloned by limiting dilution over mouse spleen feeder cells. The characteristics of the antibody were determined by adsorption against purified human chromogranins and chromogranin A, by tmmunoelectrobIot staining and by avidin-biotin-peroxidase immunohistochemistry. An extensive evaluation of antibody LK2H10 specificity is given in Wilson & Lloyd (1984) .
Immunostaining
The immunogold staining procedure (Varndell et al., 1982; VarndelI & Polak, 1983; was employed using a primary antibody dilution at 1 : 100 to 1:200 for I h at room temperature with minimal etching (2% w/v hydrogen peroxide for 2 min). Antigen-antibody complex sites were visualized using a goat anti-mouse IgG antibody adsorbed onto 10 or 20 nm colloidal gold (Janssen Pharmaceutica, Beerse, Belgium) at dilutions of I:30 and 1:10 respectively. The sections were then counterstained with uranyl acetate and lead citrate and viewed by transmission electron microscopy at 80-100 kV.
Assessment of immunostaining
The distribution of colloidal gold in different cellular compartments was quantified by counting the number of particles per unit area according to the formula:
where x is the number of gold particles associated with particular organelles per cell (e.g. secretory granules, in whole or part); a, the area of the immunostained organelles counted per cell; x', the number of gold particles per cell not associated with particular organelles ('background'); and a', the area of cell containing x' but excluding x (a should equal or approach a'). The 'nonspecific' staining was considered to be negligible if:
r>~12
Controls
Procedures for the establishment of method specificity were carried out (Van Leeuwen, 1982; at optimal primary antibody titre (1:100-1:200). Serum spedficity was ascertained by preadsorbing the anti-chromogranin serum with electrophoretically purified (dopamine-fi-hydroxylasefree) human chromogranin A (a generous gift from Dr D. T. O'Connor, Veteran's Administration Hospital, San Diego, USA; see O'Connor et al., 1984, and Lloyd, 1984 , for details of the purification procedure). The chromogranin antibody was also preadsorbed with dopm~ine-fi-hydroxylase (bovine adrenal medulla Drill;Sigma, UK) at concentrations up to 2 x 10 ~ M diluted antibody.
Results
A wide range of endocrine cell types in the gastrointestinal tract were found to exhibit chromogranin immunoreactivity. Enterochromaffin (EC) cells were particularly densely immunostained (Fig. 1) . Enteroglucagon (EG), glucose-dependent insulinotropic peptide (GIP), gastrin (IG) and neurotensin (N) storing cells were also found to contain chromogranin immunoreactive material. In all cases, chromogranin immunoreactivity was restricted to the secretory granule matrix. Immunocytochemically-identified somatostatin-containing endocrine cells in both gut and pancreas were apparently nonimmunoreactive to the chromogranin antibody (LK2HI0) when applied at the electron microscope level to tissue processed as described in this study (Fig. 2) . In the human pancreas, only one endocrine cell type was found to exhibit chromogranin immunoreactivity, the glucagon-containing (A) cell (Fig. 3) . In the alpha granules of A cells, the chromogranin immunoreactivity was localized only to the moderately electron-dense halo (Fig. 4) . Chromogranin immunoreactivity was also localized to secretory granules of normal adrenal medulla, phaeochromocytomas (Fig. 5) , a carotid body tumour, gastrinomas (Fig. 6 ) and medullary carcinomas of the thyroid. Using monoclonal antibody LK2H10 in this electron microscopical immunocytochemical study, we were unable to detect chromogranin immunoreactivity in secretory vesicles of neural origin.
The immunoreactivity of the chromogranin antibody was completely abolished by incubation with I nmol purifed chromogranin A/ml at optimal antibody titre (Fig. 7) . Preadsorption with dopamine-fi-hydroxylase had no effect on chromogranin immunostaining.
Discussion
A large number of human endocrine cell secretory granule types have been shown to exhibit chromogranin immunoreactivity. The localization of this protein to the intragranular matrix is in keeping with the preliminary findings of Aunis et. al. (1980) in bovine adrenal medulla, and Wilson & Lloyd (1984) and O'Connor et aI. (1983a O'Connor et aI. ( ,b, 1984 in human tissues, and offers some support to the contention, based on biochemical evidence presented by Sen et al. (1979) , that one rfile for chromogranin (specifically chromogranin A) is to stabilize the stored components. containing cells. Chromogranin immunoreactivi~-y (J_O nm gold particles) is localized to the A cell secretory granules (arrowed). Note in this preparation, the grid-mounted sections were incubated by immersion in all immunoreagents, thus no topographic segregation of chromogranin is evident. Scale bar, 0.5 ~m. Fig. 4 . High magnification electron micrograph of a single glucagon-containing secretory granule immunostained to reveal chromogranin immunoreactive sites. The immunoreactivity is clearly restricted to the moderately electron dense halo (large arrows). The small arrows indicate the morphological transition zone between core and halo. This preparation was immunostained by floating the grid on all immunoreagents; because there is no penetration of immunoglobulins into the section only the antigenic sites exposed on one surface are labelled. Scale bar, 0.1 vm.
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.~L~ ~ 9 Fig. 5 . Electron micrograph of secretory granules from human phaeochromocytoma intensely immunostained to reveal sites of chromogranin immunoreactivity (10 nm colloidal gold; arrowed). Scale bar, 0.5 t~m. Fig. 6 . Electron micrograph of gastrin-producing cells from the liver metastasis of a human pancreatic tumour immunostained with chromogranin monoclonal antibody LK2H10. Immunoreactive sites are restricted to the electron-dense secretory granules (arrowed). Immunogold staining procedure with I0 nm colloidal gold particles. Scale bar, 0.5 t,m.
Not all endocrine cells of the human gut exhibited chromogranin immunoreactivity (e.g. somatostatin-containing cells) using the combination of monoclonal antibody LK2H10 and the preparative procedures for transmission electron microscopy described here. It should be emphasized, however, that glutaraldehyde was used as the fixative of choice throughout this study. Van Ewijk et aI. (1984) evaluated the effect of different fixatives on monoclonal antibody binding efficiency and stressed that different antigenic determinants may react variably to different fixation protocols. This point could be reinterpreted to include the same antigenic epitope in different subcellular compartments. If, as seems likely, chromogranin conveys structural stability on a range of secretory proteins within intragranular matrices, it is reasonable to consider that the different Fig. 7 . Electron micrograph of enterochromaffin celI from human colonic mucosa. The preparation has been immunostained using monoclonal antibody LK2HI0 preadsorbed with I nmol purified human chromogranin A per ml diluted antibody. The secretory granules are not immunolabelled (cf. Fig. I ). Scale bar, 1 jim. chromogranin-secretory product complexes thus formed may react in different ways to even a single fixative. Consequently, it is necessary to consider that preparative procedures, particularly fixation, are exceedingly important if the preservation of chromogranin-immunoreactive epitopes at the ultrastructural level is to be achieved.
This 'preparation-dependent' immunolocalization is further highlighted by the highly specific alpha cell halo localization of chromogranin immunoreactivity. In their original paper, Lloyd & Wilson (1983) mentioned that glucagon-producing cells exhibited the greatest immunoreactivity to antiserum LK2H10 whereas insulin-producing cells showed the least. This finding was subsequently corroborated (Facer et aI,, 1985) . In contrast, O'Connor et aI. (1983a,b) used polyclonal antisera and recorded chromogranin A to co-exist with insulin in human and bovine pancreatic beta cells. Recently, Cohn ei al. (1984) detected the secretory protein I-chromogranin A family in somatostatin-and pancreatic polypeptide-containing, but not in insulin-or glucagon-containing cells of rat pancreatic islets. All four human pancreatic endocrine cell types have been immunostained using monoclonal antibody LK2H10 on freeze-dried tissue vapour-fixed with benzoquinone (Facet et al., 1985) . Clearly the conditions under which this antibody in particular and monoclonal antibodies in general are used must be carefully defined (see Mason et al., 1983; Van Ewijk et al., 1984) .
Whilst the differential effect of tissue preparation on the particular chromogranin epitope recognized by monoclonal antibody LK2H10 prejudices its use as a universal endocrine cell marker antibody at the electron microscopical level under routine preparative conditions, we can justifiably propose that chromogranin is the endocrine secretory granule immunodeterminant most reliably localized at the electron microscope level. Previously, an argentaffin (Hamperl, I927; Portela-Gomes & Grimelius, 1982) or argyrophil (Grimelius, I968; Grimelius & Wilander, 1984) silver impregnation cytochemical technique was necessary. It is likely that the increasing application of cryogenic techniques for transmission electron microscopy (Tokuyasu, 1984; Dudek et aI., 1984) will reduce the possibility of solvent-induced structural change which may be responsible for the loss of chromogranin antigenicity, and which is particularly encountered when monoclonal antibodies are utilized.
It is interesting to note also that chromogranin immunostaining may be of use to electron microscopists in the differential recognition of endocrine secretory granules from other subcellular organelles (e.g. primary lysosomes or exocrine storage vesicles). This is particularly relevant in cases of cytoplasmic degranulation (either natural or induced by poor fixation) which is frequently encountered in neuroendocrine neoplasms.
In conclusion, the absolute distribution of chromogranins A and B (Falkensammer et al., 1985) within endocrine tissues will only be attained with a mixture of monoclonal antibodies recognizing different epitopes. The results obtained thus far are highly encouraging in that chromogranin immunostaining has potential as an endocrine cell marker at the ultrastructural level.
